Alzheimer's Disease Clinical Trials

Trials for someone you care about with alzheimer's disease.

Brain & Nervous System

Recruiting Drug Device Behavioral Older adults Healthy volunteers

46 trials · showing 30

Testing Nabilone against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives Nabilone. Group B, the placebo group, receives Placebo.

Sites in Toronto, Calgary and 4 more cities

Phase 3
2 groups
Sites in Calgary, Hamilton and 4 more cities
Recruiting

Official title: Nabilone for Agitation Blinded Intervention Trial

Alzheimer Disease · Sunnybrook Health Sciences Centre

Testing Xanomeline/Trospium Chloride with Xanomeline Enteric against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Xanomeline/Trospium Chloride Capsule and Xanomeline Enteric Capsule. Group B, the placebo group, receives Placebo.

Sites in London, Toronto and 3 more cities

Phase 3
2 groups
Sites in Hamilton, London and 3 more cities
Recruiting

Official title: A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Alzheimer Disease · Bristol-Myers Squibb

Testing EXV-802 against a placebo for agitation associated with Alzheimer's disease dementia

Explore this study →

There are 3 groups in this study. Group A receives EXV-802. Group B, the placebo group, receives Placebo. Group C receives EXV-801.

Sites in North York, Peterborough and 1 more city

Phase 2
3 groups
Sites in Peterborough and Whitby
Recruiting

Official title: Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Agitation Associated With Alzheimer's Disease Dementia · Exciva GmbH

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for alzheimer's disease.

Testing SAR448851 against a placebo for Alzheimer's type dementia

Explore this study →

There are 2 groups in this study. Group A receives SAR448851. Group B, the placebo group, receives Placebo.

Sites in Montreal, Ottawa and 1 more city

Phase 2
2 groups
Sites in Ottawa, Toronto and 1 more city
Recruiting

Official title: A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

Dementia, Alzheimer's Type · Sanofi

Testing Trontinemab against a placebo for Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives Trontinemab. Group B, the placebo group, receives Placebo.

Sites in Toronto, Kelowna and 3 more cities

Phase 3
2 groups
Sites in Kelowna, Peterborough and 3 more cities
Recruiting

Official title: A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Alzheimer's Disease · Hoffmann-La Roche

Testing KarXT with KarX-EC against a placebo for Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives KarXT and KarX-EC. Group B, the placebo group, receives Placebo.

Sites in Greenfield Park, Halifax and 6 more cities

Phase 3
2 groups
Sites in Kelowna, Richmond and 6 more cities
Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Alzheimer's Disease · Bristol-Myers Squibb

Testing ALN-APP against a placebo for early-onset alzheimer disease

Explore this study →

There are 3 groups in this study. Groups A and C receive ALN-APP. Group B, the placebo group, receives Placebo.

Sites in Montreal and Toronto

Phase 1
3 groups
Sites in Montreal and Toronto
Recruiting

Official title: A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Early-Onset Alzheimer Disease · Alnylam Pharmaceuticals

Testing MK-2214 against a placebo for early Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives MK-2214. Group B, the placebo group, receives Placebo.

Sites in Toronto, Montreal and 1 more city

Phase 2
2 groups
Sites in Ottawa, Toronto and 1 more city
Recruiting

Official title: A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Early Alzheimer's Disease · Merck Sharp & Dohme LLC

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Explore this study →

Everyone in this study is in one group and receives No Intervention.

Sites in Toronto, Kelowna and 7 more cities

Phase 3
1 group
Sites in Kelowna, Richmond and 7 more cities
Recruiting

Alzheimers Disease · Hoffmann-La Roche

Testing KarXT for psychosis associated with Alzheimer's disease

Explore this study →

Everyone in this study is in one group and receives KarXT.

Sites in Calgary, Hamilton and 3 more cities

Phase 3
1 group
Sites in Calgary, Hamilton and 3 more cities
Recruiting

Official title: Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease · Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Testing KarXT against a placebo for psychosis associated with Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives KarXT. Group B, the placebo group, receives Placebo.

Sites in Calgary, Hamilton and 4 more cities

Phase 3
2 groups
Sites in Calgary, Hamilton and 4 more cities
Recruiting

Official title: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Psychosis Associated With Alzheimer's Disease · Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Testing KarXT with KarX-EC for alzheimer disease

Explore this study →

Everyone in this study receives KarXT and KarX-EC.

Sites in Toronto, Hamilton and 2 more cities

Phase 3
1 group
Sites in Hamilton, London and 2 more cities
Recruiting

Official title: A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Alzheimer Disease · Bristol-Myers Squibb

Testing ALN-5288 against a placebo for Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives ALN-5288. Group B, the placebo group, receives Placebo and ALN-5288.

Sites in Toronto, Montreal and 1 more city

Phase 1
2 groups
Sites in Montreal, Ottawa and 1 more city
Recruiting

Official title: A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Alzheimer's Disease · Alnylam Pharmaceuticals

Testing SNK01 against a placebo for moderate alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives SNK01. Group B, the placebo group, receives Placebo.

One site, in Ottawa

Phase 1
2 groups
One site, in Ottawa
Recruiting

Official title: Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

Moderate Alzheimer Disease · NKGen Biotech, Inc.

Testing VRDS for advance dementia

Explore this study →

Everyone in this study is in one group and receives VRDS.

One site, in Winnipeg

1 group
One site, in Winnipeg
Recruiting

Official title: Investigating the Efficacy of an Augmented Virtual Reality Driving Simulator on Institutionalized Dementia Patients

Advance Dementia · University of Manitoba

Testing ML-007C-MA against a placebo for psychosis associated with Alzheimer's disease

Explore this study →

There are 2 groups in this study. Group A receives ML-007C-MA. Group B, the placebo group, receives Placebo.

Sites in Brampton, Lévis and 2 more cities

Phase 2
2 groups
Sites in Brampton, London and 2 more cities
Recruiting

Official title: A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease · MapLight Therapeutics

Testing ARO-MAPT-SC against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives ARO-MAPT-SC. Group B, the placebo group, receives Placebo.

Sites in East York, Montreal and 1 more city

Phase 1
2 groups
Sites in East York, Toronto and 1 more city
Recruiting

Official title: Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

Alzheimer Disease · Arrowhead Pharmaceuticals

Testing Transcranial Direct Current Stimulation for alzheimer disease

Explore this study →

Everyone in this study is in one group and receives Transcranial Direct Current Stimulation.

One site, in Montreal

1 group
One site, in Montreal
Recruiting

Official title: Longitudinal Study Examining At-Home tDCS

Alzheimer Disease · Lady Davis Institute

Testing transcranial direct current stimulation against a placebo for alzheimer disease

Explore this study →

There are 3 groups in this study. Group A receives transcranial direct current stimulation and naming training. Group B, the comparison group, receives transcranial direct current stimulation and naming training. Group C, the sham group, receives transcranial direct current stimulation and naming training.

One site, in Toronto

3 groups
One site, in Toronto
Recruiting

Official title: Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease

Alzheimer Disease · Baycrest

Testing Remternetug (SC) against a placebo for alzheimers disease

Explore this study →

There are 3 groups in this study. Group A receives Remternetug (SC). Group B, the placebo group, receives Matching Placebo (Remternetug). Group C, the comparison group, receives Remternetug (SC).

Sites in Québec, Toronto and 2 more cities

Phase 2
3 groups
Sites in Vancouver, Toronto and 2 more cities
Recruiting

Official title: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Alzheimers Disease · Washington University School of Medicine

Comparing 4 approaches for frontotemporal dementia

Explore this study →

There are 4 groups in this study. Groups A, B, C and D receive one or more of: Intrathalamic AAV.PGRN administration and Intrathalamic AVB-101.

One site, in Toronto

Phase 1
4 groups
One site, in Toronto
Recruiting

Official title: A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Frontotemporal Dementia · AviadoBio Ltd

Testing Active Brainsway H7-Coil Deep TMS System with Cognitive Training against a placebo for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives Cognitive Training, together with one or more of: Active Brainsway H7-Coil Deep TMS System. Group B, the sham group, receives Cognitive Training, together with one or more of: Sham Brainsway H7-Coil Deep TMS System.

One site, in Toronto

2 groups
One site, in Toronto
Recruiting

Official title: dTMS for Subjective Cognitive Decline

Alzheimer Disease · Rotman Research Institute at Baycrest

Testing Remternetug against a placebo for alzheimers disease

Explore this study →

There are 3 groups in this study. Group A receives Remternetug. Group B, the placebo group, receives Matching Placebo (Remternetug). Group C, the comparison group, receives Remternetug.

Sites in Québec, Toronto and 2 more cities

Phase 2
3 groups
Sites in Vancouver, Toronto and 2 more cities
Recruiting

Official title: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Alzheimers Disease · Washington University School of Medicine

Comparing 6 approaches for dementia

Explore this study →

There are 6 groups in this study. Group A receives Transcranial Direct Current Stimulation (tDCS). Group B receives 30 Hz Transcranial Alternating Current Stimulation (tACS). Group C receives 50 Hz Transcranial Alternating Current Stimulation (tACS). …and 3 more groups.

One site, in Winnipeg

6 groups
One site, in Winnipeg
Recruiting

Official title: Longitudinal Study to Investigate Different Transcranial Electrical Stimulation

Dementia; Degenerative, Dementia Mixed · University of Manitoba

Testing Trontinemab against a placebo for alzheimers disease

Explore this study →

There are 2 groups in this study. Group A receives Trontinemab. Group B, the placebo group, receives Placebo.

Sites in Toronto, Montreal and 3 more cities

Phase 3
2 groups
Sites in Richmond, Toronto and 2 more cities
Recruiting

Official title: A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease · Hoffmann-La Roche

Comparing Methylphenidate with intermittent theta burst stimulation for alzheimer s disease

Explore this study →

There are 2 groups in this study. Group A receives one or more of: intermittent theta burst stimulation (iTBS) and Methylphenidate (MPH). Group B receives intermittent theta burst stimulation (iTBS).

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

Alzheimer s Disease · Sunnybrook Health Sciences Centre

Testing EEG-triggered TMS for dementia

Explore this study →

Everyone in this study is in one group and receives EEG-triggered TMS.

One site, in Hamilton

1 group
One site, in Hamilton
Recruiting

Official title: Brain Wave Informed Non-invasive Brain Stimulation: Improving Neural Networks of Working Memory in Dementia: a Proof-of-concept Study

Dementia · McMaster University

Comparing Aerobic exercise with Stretch and Strength for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives Aerobic exercise. Group B receives Stretch and Strength.

One site, in Calgary

2 groups
One site, in Calgary
Recruiting

Official title: Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias

Alzheimer Disease · University of Calgary

Testing tDCS and Cognitive Training against a placebo for alzheimer disease

Explore this study →

There are 3 groups in this study. Group A receives tDCS and Cognitive Training. Group B, the comparison group, receives tDCS and Cognitive Training. Group C, the sham group, receives tDCS and Cognitive Training.

One site, in Toronto

3 groups
One site, in Toronto
Recruiting

Official title: Understanding How Alzheimer's Disease Impacts the Therapeutic Response to Transcranial Direct Current Stimulation

Alzheimer Disease · Baycrest

Comparing methylphenidate with rTMS for alzheimer disease

Explore this study →

There are 2 groups in this study. Group A receives rTMS and methylphenidate. Group B receives rTMS.

One site, in Toronto

2 groups
One site, in Toronto
Recruiting

Official title: rTMS for Apathy Clinical Trial

Alzheimer Disease · Sunnybrook Health Sciences Centre

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Alzheimer's Disease trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.